Search

NBC News anchor Craig Melvin led MSK experts in a discussion about racial and age trends in colorectal cancer and when people should start screening for the disease.

… Monday, September 19, 2022 NBC News’ Today Show anchor and co-host Craig Melvin led a discussion at Memorial Sloan Kettering Cancer Center (MSK) in March 2022 with colorectal oncologists  Fiyinfolu Balogun  and  Andrea Cercek and gastroenterologist  Robin Mendelsohn . Drs. Cercek and Mendelsohn are Co-Directors

R1 RCM Inc. and Memorial Sloan Kettering today announced a collaboration to develop a new, personalized digital financial experience for patients.

… Monday, November 1, 2021 R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, through its recent acquisition of VisitPay, today announced a collaboration with Memorial Sloan Kettering Cancer

A clinical trial at MSK found that music therapy for cancer-related anxiety is as effective as cognitive behavioral therapy and produces long-lasting benefits.

… Tuesday, January 6, 2026 Anxiety was not new to Cynthia Malaran when she was diagnosed with breast cancer , at the age of 39. The professional DJ and writer from New York City had seen a therapist to help with her feelings of anxiety in the past, but a cancer diagnosis and treatment had made it harder

At MSK, our goal is not just to train the scientists of tomorrow, but the scientific leaders.

… Monday, September 18, 2023 When Direna Alonso-Curbelo, PhD, was a graduate student in Madrid, she had the opportunity to visit Memorial Sloan Kettering Cancer Center (MSK) for a summer-long internship. That gave her a taste of what it was like to live and breathe science at one of the world’s premier

The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic mutation called a TRK fusion. Today’s decision marks a transformation in the field of precision medicine as this is the first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval, meaning that the drug was approved based on mutation type rather than on where in the body the tumor originated.

… Monday, November 26, 2018 Bottom Line VIDEO | 02:42 Rihanna's Story of Treatment on a Clinical Trial with Larotrectinib Meet Rihanna, who was on a clinical trial with larotrectinib. Video Details The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval of new drugs and new indications in multiple myeloma clinical trials.

… Thursday, August 8, 2024 A Q&A with MSK Experts  MSK played a central role in the U.S. Food and Drug Administration (FDA)  Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval

Meet Lisa DeAngelis, MSK's new Physician-in-Chief. She discusses her upbringing, her early career at MSK, and her top priorities as physician-in-chief.

… Thursday, January 2, 2020 Summary Lisa DeAngelis, the new Physician-in-Chief, has deep roots at MSK. After more than 30 years at Memorial Sloan Kettering, Lisa DeAngelis still gets up at 6 a.m. , goes to the gym if she’s feeling ambitious, and walks to and from work with her husband, Peter Okin, a cardiology

Thank you to our donor community. Your commitment to supporting Memorial Sloan Kettering Cancer Center (MSK) is essential to advancing our mission.

… Friday, April 1, 2022 Thank you to our donor community. Your commitment to supporting Memorial Sloan Kettering Cancer Center (MSK) is essential to advancing our mission. Read more to learn about your impact. Fundraising Events at MSK Cycle for Survival’s 2022 Season and 2021 Allocations Cycle for Survival

MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Kravis WISE fellowship grant recipients.

… Tuesday, March 11, 2025 MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Kravis WISE fellowship grant recipients. This year’s winners are postdoctoral fellows  Almudena Chaves-Pérez, PhD , and Adriana Mujal, PhD , and graduate students  Hina Shah and

Memorial Sloan Kettering Cancer Center is leading an innovative initiative to reduce cancer and cardiovascular health disparities in South Asian immigrant communities in the United States.

… Thursday, September 19, 2013 Memorial Sloan Kettering Cancer Center is leading an innovative initiative to reduce cancer and cardiovascular health disparities in South Asian immigrant communities in the United States. The effort, called South Asian Health: From Research to Practice and Policy , is the